MX2022010621A - Anticuerpos anti-cd19 humano. - Google Patents
Anticuerpos anti-cd19 humano.Info
- Publication number
- MX2022010621A MX2022010621A MX2022010621A MX2022010621A MX2022010621A MX 2022010621 A MX2022010621 A MX 2022010621A MX 2022010621 A MX2022010621 A MX 2022010621A MX 2022010621 A MX2022010621 A MX 2022010621A MX 2022010621 A MX2022010621 A MX 2022010621A
- Authority
- MX
- Mexico
- Prior art keywords
- antibodies
- human
- compositions
- present disclosure
- methods
- Prior art date
Links
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 abstract 4
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 abstract 4
- 101100383038 Homo sapiens CD19 gene Proteins 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Transplantation (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
La presente descripción se refiere a anticuerpos que se unen a CD19 humano ("anticuerpos anti-CD19 humano" o "anticuerpos anti-CD19 humano"), composiciones que comprenden dichos anticuerpos anti-CD19 humano y métodos para usar dichos anticuerpos anti-CD19 humano.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062983093P | 2020-02-28 | 2020-02-28 | |
| PCT/US2021/018989 WO2021173471A1 (en) | 2020-02-28 | 2021-02-22 | Anti-human cd19 antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022010621A true MX2022010621A (es) | 2022-11-30 |
Family
ID=74885029
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022010621A MX2022010621A (es) | 2020-02-28 | 2021-02-22 | Anticuerpos anti-cd19 humano. |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US11623956B2 (es) |
| EP (1) | EP4110815A1 (es) |
| JP (1) | JP7450743B2 (es) |
| KR (1) | KR20220132579A (es) |
| CN (1) | CN115151570A (es) |
| AR (1) | AR121370A1 (es) |
| AU (1) | AU2021225792A1 (es) |
| BR (1) | BR112022015902A2 (es) |
| CA (1) | CA3169155A1 (es) |
| CL (1) | CL2022002329A1 (es) |
| CO (1) | CO2022012212A2 (es) |
| CR (1) | CR20220421A (es) |
| DO (1) | DOP2022000173A (es) |
| EC (1) | ECSP22067275A (es) |
| IL (1) | IL295494A (es) |
| JO (1) | JOP20220204A1 (es) |
| MX (1) | MX2022010621A (es) |
| PE (1) | PE20221593A1 (es) |
| TW (1) | TWI790548B (es) |
| WO (1) | WO2021173471A1 (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202346576A (zh) | 2022-04-13 | 2023-12-01 | 新加坡商泰莎治療有限公司 | 治療性t細胞產品 |
| US20230399375A1 (en) | 2022-04-15 | 2023-12-14 | Kyverna Therapeutics, Inc. | Methods and compositions for treating autoimmune disease |
| WO2023240064A1 (en) | 2022-06-08 | 2023-12-14 | Kyverna Therapeutics, Inc. | Methods and compositions for treating autoimmune disease |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1966245E (pt) | 2005-12-30 | 2011-08-31 | Merck Patent Gmbh | Anticorpos anti-cd19 com imunogenicidade reduzida |
| US8323653B2 (en) * | 2006-09-08 | 2012-12-04 | Medimmune, Llc | Humanized anti-CD19 antibodies and their use in treatment of oncology, transplantation and autoimmune disease |
| WO2015171863A1 (en) | 2014-05-08 | 2015-11-12 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. | USING B-CELL-TARGETING ANTIGEN IgG FUSION AS TOLEROGENIC PROTEIN THERAPY FOR TREATING ADVERSE IMMUNE RESPONSES |
| CA3026880A1 (en) | 2016-06-08 | 2017-12-14 | Paul Foster | Treatment of igg4-related diseases with anti-cd19 antibodies crossbinding to cd32b |
-
2021
- 2021-02-18 TW TW110105560A patent/TWI790548B/zh active
- 2021-02-18 AR ARP210100425A patent/AR121370A1/es unknown
- 2021-02-22 CR CR20220421A patent/CR20220421A/es unknown
- 2021-02-22 IL IL295494A patent/IL295494A/en unknown
- 2021-02-22 PE PE2022001851A patent/PE20221593A1/es unknown
- 2021-02-22 AU AU2021225792A patent/AU2021225792A1/en active Pending
- 2021-02-22 EP EP21712613.5A patent/EP4110815A1/en active Pending
- 2021-02-22 BR BR112022015902A patent/BR112022015902A2/pt unknown
- 2021-02-22 KR KR1020227029214A patent/KR20220132579A/ko active Search and Examination
- 2021-02-22 CA CA3169155A patent/CA3169155A1/en active Pending
- 2021-02-22 WO PCT/US2021/018989 patent/WO2021173471A1/en active Application Filing
- 2021-02-22 JO JOP/2022/0204A patent/JOP20220204A1/ar unknown
- 2021-02-22 CN CN202180016785.XA patent/CN115151570A/zh active Pending
- 2021-02-22 MX MX2022010621A patent/MX2022010621A/es unknown
- 2021-02-22 JP JP2022551767A patent/JP7450743B2/ja active Active
- 2021-02-22 US US17/181,184 patent/US11623956B2/en active Active
-
2022
- 2022-08-25 CL CL2022002329A patent/CL2022002329A1/es unknown
- 2022-08-26 CO CONC2022/0012212A patent/CO2022012212A2/es unknown
- 2022-08-26 EC ECSENADI202267275A patent/ECSP22067275A/es unknown
- 2022-08-26 DO DO2022000173A patent/DOP2022000173A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2021173471A1 (en) | 2021-09-02 |
| CN115151570A (zh) | 2022-10-04 |
| AU2021225792A1 (en) | 2022-09-15 |
| TW202146451A (zh) | 2021-12-16 |
| JOP20220204A1 (ar) | 2023-01-30 |
| US20210269520A1 (en) | 2021-09-02 |
| CR20220421A (es) | 2022-09-23 |
| DOP2022000173A (es) | 2022-10-31 |
| CO2022012212A2 (es) | 2022-09-09 |
| AR121370A1 (es) | 2022-06-01 |
| JP7450743B2 (ja) | 2024-03-15 |
| PE20221593A1 (es) | 2022-10-10 |
| KR20220132579A (ko) | 2022-09-30 |
| BR112022015902A2 (pt) | 2022-10-04 |
| CL2022002329A1 (es) | 2023-04-10 |
| JP2023515219A (ja) | 2023-04-12 |
| TWI790548B (zh) | 2023-01-21 |
| IL295494A (en) | 2022-10-01 |
| US11623956B2 (en) | 2023-04-11 |
| ECSP22067275A (es) | 2022-09-30 |
| CA3169155A1 (en) | 2021-09-02 |
| EP4110815A1 (en) | 2023-01-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202211057B (en) | Anti-trem2 antibodies and methods of use thereof | |
| PH12021550337A1 (en) | Anti-gdf15 antibodies, compositions and methods of use | |
| CR20220421A (es) | Anticuerpos anti-cd19 humano | |
| WO2017062672A3 (en) | Anti-trem2 antibodies and methods of use thereof | |
| WO2017075432A3 (en) | Anti-siglec-9 antibodies and methods of use thereof | |
| MX2020011828A (es) | Anticuerpos anti proteina alfa reguladora de se?ales (sirpa) y metodos de uso de los mismos. | |
| PH12021550690A1 (en) | Anti-hla-g antibodies, compositions comprising anti-hla-g antibodies and methods of using anti-hla-g antibodies | |
| EA201792221A1 (ru) | Антитела против сортилина и способы их применения | |
| PH12019502463A1 (en) | Anti-cd33 antibodies and methods of use thereof | |
| MX2019012869A (es) | Anticuerpos anti-sortilina y metodos para su uso. | |
| MX2020013324A (es) | Anticuerpos anti proteína reguladora de señales beta 1 (sirp-beta1) y métodos de uso de los mismos. | |
| MX2021002690A (es) | Anticuerpos anti-avb8 y composiciones y usos de los mismos. | |
| MX2022007231A (es) | Anticuerpos anti-mertk y metodos de uso de los mismos. | |
| CR20220078A (es) | Anticuerpos anti-ms4a4a y métodos de uso de los mismos | |
| MX2021000933A (es) | Anticuerpos anti-siglec-5 y métodos para su uso. | |
| MX2019009498A (es) | Anticuerpos mimeticos de fgf21 y usos de los mismos. | |
| EA202092508A1 (ru) | Составы на основе антител к pd-l1 человека | |
| MX2021006362A (es) | Anticuerpos de dominio simple contra cll-1. | |
| MX2022001449A (es) | Compuestos de aminoesterol humano ent-03, composiciones relacionadas que comprenden los mismos y metodos para usar los mismos. | |
| MX2021015156A (es) | Anticuerpos anti-pcrv que se unen a pcrv, composiciones que comprenden anticuerpos anti-pcrv, y metodos de uso de estos. | |
| MX2020013172A (es) | Anticuerpos anti-siglec-7 y sus metodos de uso. | |
| MX2021000287A (es) | Composiciones y métodos relacionados con constructos de dominio de unión a antígeno-fc modificados genéticamente. | |
| MX2021000280A (es) | Composiciones y métodos relacionados con constructos de dominio de unión a antígeno-fc modificados genéticamente. | |
| ZA202205813B (en) | Trpv1 epitopes and antibodies | |
| CR20240046A (es) | Anticuerpos contra el receptor alfa de la interleucina-4 humana |